Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:37:12.187Z.
Calculation as of: 2026-10-06T17:37:12.187Z.
Quote observation: 2026-10-06T17:34:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1439c3a9e54fb1f97ae208c5489c534aa692153c8f3b45d8dac24981f451ae3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$22.11M
Price/FCF Ratio
6.80
TTM Avg
13.56
3Y Avg
13.45
5Y Avg
13.45
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.36M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | 6.80 | 13.56 | 13.45 | 13.45 |
| Quantum BioPharma Ltd. (QNTM)vs › | $21.05M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.89M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.44M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | 7.46 | 10.70 | 8.48 | 6.39 |
| iTonic Holdings Ltd. (ITOC)vs › | $26.39M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.21M | N/A | 118.09 | 118.84 | 145.02 |
| P3 Health Partners Inc. (PIII)vs › | $19.67M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.51M | N/A | 242.89 | 242.89 | 242.89 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
